This educational and promotional event is organised and funded by Flynn Pharma Ltd.
Event Details
In-person event details
Additional Information: Due to the expected popularity of this event early booking is advised. Physical spaces for this meeting are limited and will be allocated on a first come, first served basis.
Agenda
Meet the Speakers
Dr Carsten Vogt is a consultant child & adolescent psychiatrist and clinical lead for the ADHD Specialist CAMHS pathway at CYPF Berkshire. Dr Vogt has a special interest in the use of objective measurements for diagnostic assessment and measuring of treatment response in ADHD. He introduced the QbTest as part of the standard routine ADHD assessment in Berkshire in 2008 and published several papers on its clinical application. Dr Vogt has a particular interest in the effects of physical exercise on alleviating symptoms of ADHD and its consideration as a therapeutic intervention or adjunct with standard treatments for ADHD.
With over 12 years’ experience as a paediatric/neonatal doctor in the NHS working in paediatric units, including neonatal intensive care units. Dr Datt has a specialist interest in neurology, rare paediatric diseases, and developmental clinics, with associated mental health disorders including Autism Spectrum Disorder (ASD), and Attention Deficit Hyperactivity Disorder (ADHD). Dr Datt’s research interests include rare paediatric diseases such as Mucopolysaccharidoses (MPS), Paediatric Multiple Sclerosis, Haemophilia, Sickle Cell Anaemia, Beta-thalassaemia, X-Linked Hypophosphatemia (XLH), Vitamin D deficiency, Achondroplasia, Primary Immunodeficiencies (PID’s), and oncology (especially Astrocytoma and Neuroblastoma) in both small molecule therapeutics, biologics, and gene therapy. As a postgraduate tutor and board of examiner with the Faculty of Pharmaceutical Medicine (FPM), Dr Datt is a revalidation appraiser on behalf of the Royal College of Physicians for FPM. His passion for delivering optimum client-focused care, extends as he continues to teach junior doctors, delivering medical education and raising awareness of rare paediatric conditions. After completing a degree in Biological Medicinal Chemistry with Drug Design (BSc.), Dr Datt acquired a postgraduate diploma in Pharmaceutical Medicine from Oxford and graduated from Medical School (MBBS) from the University of East Anglia. He has also undertaken postgraduate certificates and diplomas in child health as well as conducting research in gastro-oesophageal reflux disease and leukaemia at the National Institute for Health (NIH) in Maryland, USA.
Professor Raja Mukherjee is an Adult Learning Disability Consultant Psychiatrist for Surrey and Borders Partnership NHS Foundation Trust, with interest in the management of developmental disorders across the lifespan. In September 2009 he started the first NHS based specialist Fetal Alcohol Spectrum Disorders behavioural clinic and since then has seen over 250 cases for specialist second opinion as a national referral service. Dr Mukherjee completed his PhD on the subject of Fetal Alcohol Syndrome in 2014. He has also acted as an invited advisor to the BMA board of science, The Department of Health and the World Health Organisation on the subject of FASD. In 2015 Dr Mukherjee also gave evidence to the first All Party Parliamentary Group on FASD at the House of Commons. He has continued to support national clinical developments related to FASD. Dr Mukherjee is a member of the NICE quality standards group for FASD. He is currently the only UK representative to a US, NIH sponsored initiative to consider the research criteria for FASD. In his own time, he volunteers as a medical advisor to various FASD charities both in the UK and internationally. In 2021 he was made an Honorary Professor at the University of Salford related to his work on FASD. In wider work, he is currently the Clinical Lead for Adult neurodevelopmental services provided by Surrey and Borders including Adult ASD and ADHD services across Surrey, Hampshire and Portsmouth. He is a an executive committee member of the RCPsych SIG on neurodevelopmental disorders, taking over as Finance officer from July 2021.
Ashley is Consultant Paediatric Neuropsychiatrist in the tertiary paediatric neurodevelopmental service at the Evelina London Children’s Hospital, and in the paediatric liaison mental health service (National and Specialist CAMHS) at South London and Maudsley NHS Foundation Trust. His clinical expertise and academic interests are in neurodevelopmental conditions (intellectual disabilities, autism, ADHD, tics), mental health conditions co-occurring with neurological conditions (epilepsy, neuroinflammatory conditions, brain injury), and complex psychopharmacology (in children with neurological and cardiac conditions).
Ashley trained previously in Paediatrics and has postgraduate qualifications in Clinical Neuropsychiatry and Digital Health Leadership. He is an Honorary Associate Professor at the University of Warwick, and Honorary Senior Research Fellow at the University of Birmingham. Ashley is Joint Chair of the Scientific Advisory Committee of the Smith-Magenis Syndrome Foundation, and has held leadership and advisory positions at the Royal College of Psychiatrists, NICE, Health Education England, and NHS England.
What will the event cover?
Key learning objectives
- To understand the treatment options available for the management of ADHD in children and young people
- To review the impact of COVID on ADHD assessments and the resulting service improvements made within a community paediatric setting
- To explore the diagnosis and management of ADHD and comorbid conditions including Foetal Alcohol Spectrum Disorders (FASD)
- To look at a range of approaches for the effective management of sleep difficulties in young people with neurodevelopmental disorders
- To examine the efficacy of ADHD treatments for children and young people using objective measures